Otsuka's pharma sales up but drop-outs hit oncology pipeline
This article was originally published in Scrip
Executive Summary
Otsuka's pharmaceuticals business reported sales of ¥715.9 billion ($7.79 billion), a 6% rise, in the fiscal year to 31 March, accounting for two thirds of net sales at its parent, Otsuka Holdings.